![](https://s3.amazonaws.com/cache.altmetric.com/policy/thumbnails/thumbnail-890ae112dbe05104348e7d36e6deea95209ebcc9977aeed5c20e9adb7c8bf47c.jpg)
Octreotide Long-Acting Release and Everolimus for Recurrent Meningiomas
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.